| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -38,441 |
| Depreciation and amortization | 6 |
| Non-cash interest expense | 489 |
| Stock-based compensation expense | 15,340 |
| Accretion/amortization of premium/discount of available-for-sale securities | 33 |
| Amortization of right of use-assets | 466 |
| Gain on early extinguishment of lease liability | 149 |
| Loss on disposal of property and equipment | 0 |
| Non-cash research and development expenses for the common stock issuable pursuant to hutchmed agreement | 0 |
| Prepaid expenses and other current assets | 3,574 |
| Other non-current assets | 1,277 |
| Accounts payable | -2,179 |
| Accrued expenses and other current liabilities | -9,945 |
| Deferred revenue | -650 |
| Operating lease liabilities | -694 |
| Other long-term liabilities | 15 |
| Net cash used in operating activities | -40,626 |
| Cash divested in non-ox40 divestiture | 5,215 |
| Proceeds from disposal of property and equipment | 0 |
| Purchases of marketable securities | 1,485 |
| Maturities and sales of marketable securities | 2,250 |
| Net cash provided by investing activities | -4,450 |
| Proceeds from term loan | 15,000 |
| Proceeds from exercise of stock options | 45 |
| Issuance costs in connection with reverse recapitalization | -5,338 |
| Cash acquired in connection with reverse recapitalization | -54,631 |
| Proceeds from common stock issued in pipe financing, net of issuance costs | 71,130 |
| Net cash provided by financing activities | 135,468 |
| Effects of exchange rates on cash and cash equivalents | 652 |
| Net increase (decrease) in cash and cash equivalents | 91,044 |
| Cash and cash equivalents at beginning of period | 12,118 |
| Cash and cash equivalents at end of period | 103,162 |
ImageneBio, Inc. (IMA)
ImageneBio, Inc. (IMA)